CSPC PHARMACEUT.GR. ADR4

Research CSPC PHARMACEUT.GR. ADR4 (CVGU) on Bullrun: valuation model: 13.2% undervalued, market cap EUR 7.98B, P/E 15.6, dividend yield 4.4%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

TickerCVGU
ExchangeF
CountryChina
SectorHealthcare
IndustryDrug Manufacturers - General
CurrencyEUR
Valuation signal13.2% undervalued
Market capEUR 7.98B
P/E15.6
Dividend yield4.4%
Financial periodFY2025
RevenueEUR 26.01B
Revenue growth-10.4%
Net incomeEUR 3.88B
Free cash flowEUR 3.55B
Gross margin65.6%

Valuation Snapshot

Bullrun's latest valuation model marks CSPC PHARMACEUT.GR. ADR4 as 13.2% undervalued; latest market cap is EUR 7.98B; P/E is 15.6; dividend yield is 4.4%.

About CSPC PHARMACEUT.GR. ADR4

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment;

Frequently asked questions

Is CSPC PHARMACEUT.GR. ADR4 overvalued or undervalued?

Bullrun's valuation model currently marks CSPC PHARMACEUT.GR. ADR4 as 13.2% undervalued.

What is CSPC PHARMACEUT.GR. ADR4's market cap?

CSPC PHARMACEUT.GR. ADR4's market capitalization is EUR 7.98B.

What is CSPC PHARMACEUT.GR. ADR4's P/E ratio?

CSPC PHARMACEUT.GR. ADR4's price-to-earnings (P/E) ratio is 15.6.

Does CSPC PHARMACEUT.GR. ADR4 pay a dividend?

CSPC PHARMACEUT.GR. ADR4 has a dividend yield of 4.4%.